STANDARD BIOTOOLS INC. (LAB) — insider trading
Health Care · NASDAQ
STANDARD BIOTOOLS INC. (LAB) has 23 reported SEC Form 4 insider transactions in our data (latest 2026-06-20).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-06-20 | Mackay Sean | Officer (SVP & Chief Business Officer) | Grant / award / vesting | 500,000 | $0.00 | $0 | Form 4 |
| 2026-06-18 | HIBBS KATHY L | Director | Grant / award / vesting (derivative) | 175,923 | $0.00 | $0 | Form 4 |
| 2026-06-18 | HIBBS KATHY L | Director | Grant / award / vesting | 99,116 | $0.00 | $0 | Form 4 |
| 2026-06-18 | ELOI FENEL M | Director | Grant / award / vesting (derivative) | 175,923 | $0.00 | $0 | Form 4 |
| 2026-06-18 | ELOI FENEL M | Director | Grant / award / vesting | 99,116 | $0.00 | $0 | Form 4 |
| 2026-06-18 | Cox Troy | Director | Grant / award / vesting (derivative) | 175,923 | $0.00 | $0 | Form 4 |
| 2026-06-18 | Cox Troy | Director | Grant / award / vesting | 99,116 | $0.00 | $0 | Form 4 |
| 2026-06-18 | Casdin Eli | Director, 10% owner | Grant / award / vesting (derivative) | 175,923 | $0.00 | $0 | Form 4 |
| 2026-06-18 | Casdin Eli | Director, 10% owner | Grant / award / vesting | 99,116 | $0.00 | $0 | Form 4 |
| 2026-06-18 | Witney Frank | Director | Grant / award / vesting (derivative) | 175,923 | $0.00 | $0 | Form 4 |
| 2026-06-18 | Witney Frank | Director | Grant / award / vesting | 99,116 | $0.00 | $0 | Form 4 |
| 2026-06-18 | Carey Thomas D. | Director | Grant / award / vesting (derivative) | 263,884 | $0.00 | $0 | Form 4 |
| 2026-06-18 | Carey Thomas D. | Director | Grant / award / vesting | 99,116 | $0.00 | $0 | Form 4 |
| 2026-05-20 | Egholm Michael | Director, Officer (President & CEO) | Shares withheld for taxes / exercise cost | 97,626 | $1.00 | $97.6K | Form 4 |
| 2026-05-20 | Mackay Sean | Officer (SVP & Chief Business Officer) | Shares withheld for taxes / exercise cost | 25,729 | $1.00 | $25.7K | Form 4 |
| 2026-05-20 | Kim Hanjoon Alex | Officer (Chief Financial Officer) | Shares withheld for taxes / exercise cost | 18,871 | $1.00 | $18.9K | Form 4 |
| 2026-04-06 | Egholm Michael | Director, Officer (President & CEO) | Option exercise / conversion (derivative) | 196,513 | $0.00 | $0 | Form 4 |
| 2026-04-06 | Egholm Michael | Director, Officer (President & CEO) | Shares withheld for taxes / exercise cost | 95,014 | $0.91 | $86.3K | Form 4 |
| 2026-04-06 | Egholm Michael | Director, Officer (President & CEO) | Option exercise / conversion | 196,513 | $0.00 | $0 | Form 4 |
| 2026-03-20 | Mackay Sean | Officer (SVP & Chief Business Officer) | Grant / award / vesting (derivative) | 612,240 | $0.00 | $0 | Form 4 |
| 2026-03-20 | Mackay Sean | Officer (SVP & Chief Business Officer) | Grant / award / vesting | 272,107 | $0.00 | $0 | Form 4 |
| 2026-03-20 | Egholm Michael | Director, Officer (President & CEO) | Grant / award / vesting (derivative) | 2,345,340 | $0.00 | $0 | Form 4 |
| 2026-03-20 | Egholm Michael | Director, Officer (President & CEO) | Grant / award / vesting | 1,042,373 | $0.00 | $0 | Form 4 |
Ask the chat about LAB's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: STANDARD BIOTOOLS INC. (LAB).
Last updated 2026-06-20 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.